ArticleCureus2026
Impact of Switching Between Different Brands of Levothyroxine on Maintaining Normal Thyrotropin Levels: A Prospective, Multicenter, Phase IV Clinical Trial.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background This study aimed to evaluate the impact of a switch from Thyronorm or Eltroxin tablets to Lethyrox tablets on serum thyroid-stimulating hormone (TSH) levels in participants with primary hypothyroidism who were stable on Thyronorm or Eltroxin. Methodology Patients aged 18 to 65 years diagnosed with primary hypothyroidism for at least a year, who were taking a stable dose of levothyroxine tablets (Thyronorm or Eltroxin) for at least the last eight weeks and had normal serum TSH levels (0.465 to 4.68 mIU/L), were included in this prospective, multicenter, phase IV clinical trial. For a period of 18 weeks, the patients were transferred to Lethyrox tablets at the same dosage they had previously been taking. The percentage of patients with normal blood TSH levels after six weeks of switching was the main study objective. Results A total of 150 patients were enrolled, with a mean (SD) age of 45 (11) years, including 104 (69.3%) females. The mean (SD) serum TSH at baseline was 2.49 (1.12) mIU/L. Overall, 142 patients qualified for the intent-to-treat analysis. Of these, 111 (78.2%) patients maintained normal serum TSH values after six weeks of switching to Lethyrox tablet. The serum TSH level was within the normal reference range for 104 (73.2%) patients and 108 (76.1%) patients after 12 and 18 weeks of switching, respectively. A dose change was not required in 129 (90.84%) patients after switching to Lethyrox tablet at weeks 6 and 12, respectively. The mean (SD) TSH values at 6, 12, and 18 weeks were 3.55 (7.90), 3.71 (4.83), and 3.00 (2.03) mIU/L, respectively. Conclusions In the majority of individuals with primary hypothyroidism, switching brands of levothyroxine tablets was safe as it did not result in clinically significant changes in serum TSH levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.